Schizophrenia Clinical Trials Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Schizophrenia Pipeline Insight' report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Schizophrenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Schizophrenia Treatment Landscape. Click here to read more @ Schizophrenia Pipeline Outlook
Key Takeaways from the Schizophrenia Pipeline Report
In June 2025, Bristol-Myers Squibb announced a study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia.
In June 2025, Teva Branded Pharmaceutical Products R&D Inc. conducted a study will be composed of 2 periods: Period 1 (the double-blind, placebo-controlled, efficacy and safety period) and Period 2 (open-label long term safety period). For each participant, the duration of Period 1 will be 8 weeks, and the duration of Period 2 will be up to 48 weeks. In Period 1, participants will be randomized to one of 3 TV-44749 treatment groups or a placebo group in a 1:1:1:1 ratio.
DelveInsight's Schizophrenia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Schizophrenia treatment.
The leading Schizophrenia Companies such as Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
Promising Schizophrenia Therapies such as x Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.
Stay informed about the cutting-edge advancements in Schizophrenia treatments. Download for updates and be a part of the revolution in cancer care @ Schizophrenia Clinical Trials Assessment
Schizophrenia Emerging Drugs Profile
Ulotaront: Sunovion Pharmaceuticals
SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Currently, the drug is in the Phase III stage of its development for the treatment of Schizophrenia
Emraclidine: Abbvie
Emraclidine is a selective M4 receptor PAM, meaning it selectively targets the M4 receptor to harness the anti-psychotic effect believed to be associated with this receptor while minimizing the side effects associated with other pan-muscarinic agonists. The company believes emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development. Currently, the drug is in the Phase II stage of its development for the treatment of Schizophrenia.
CY 6463: Cyclerion Therapeutics
CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. By compensating for deficient NO-sGC-cGMP signaling, CY6463 and other sGC stimulators may have broad therapeutic potential as a treatment to improve cognition and function in people with serious CNS diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Schizophrenia.
Learn more about Schizophrenia Drugs opportunities in our groundbreaking Schizophrenia Research and development projects @ Schizophrenia Unmet Needs
Schizophrenia Companies
Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Schizophrenia Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Discover the latest advancements in Schizophrenia treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Schizophrenia Market Drivers and Barriers, and Future Perspectives
Scope of the Schizophrenia Pipeline Report
Coverage- Global
Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others.
Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others
Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Schizophrenia Pipeline on our website @ Schizophrenia Emerging Drugs and Companies
Table of Content
Introduction
Executive Summary
Schizophrenia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Schizophrenia– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
LYN-005: Lyndra Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Emraclidine: Abbvie
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
KYN-5356: Kynexis
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Schizophrenia Key Companies
Schizophrenia Key Products
Schizophrenia- Unmet Needs
Schizophrenia- Market Drivers and Barriers
Schizophrenia- Future Perspectives and Conclusion
Schizophrenia Analyst Views
Schizophrenia Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/undefined
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
4 hours ago
- National Post
Industrial 3-axis accelerometer has high offset stability
Article content KYOTO, Japan — Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has introduced a 3-axis accelerometer for the industrial market that combines high offset stability over temperature and time, good linearity, low noise density, and excellent robustness. The SCA3400-D01 XYZ accelerometer is meant for use in industrial applications such as structural health monitoring (SHM), machine control, inertial measurement units, and construction tools and systems. This product will be exhibited at Sensors Converge 2025 to be held at the Santa Clara Convention Center (Booth #716), California from 24 to 26 June 2025. Article content The offset stability of an accelerometer refers to the consistency of its output when at rest, but subject to varying temperatures or the effects of aging. Ideally, this output should be zero, but it is often not, and so equipment makers need to calibrate their designs to account for this. The more stable the offset is, the greater the accuracy of the sensor's measurements. Also, high offset stability enables equipment makers to calibrate their designs for the product's lifetime, rather than expecting users to regularly recalibrate to maintain accuracy. Article content In the case of the SCA3400-D01, the offset drift over lifetime 0.5 mg for the X and Y axes and 2 mg for the Z axis. The offset error introduced by varying its operating temperature is 2 mg on the X and Y axes and 3 mg on the Z axis. The Murata SCA3400-D01 offers exceptional performance in terms of accuracy. It exhibits a linearity error figure of 1 mg over a 1.2 g range and a noise density of 20 µg/√Hz, both of which contribute to more precise measurements. Article content Another feature of the 3-axis accelerometer that should appeal to industrial equipment makers is the user-selectable dynamic range and low-pass filtering, which enables designers to configure the part for the best combination of resolution, linearity, and noise performance for the application. The part also has self-diagnostic features that enable it to detect when a measured signal is reliable. Article content The SCA3400-D01 (8.6 × 7.6 × 3.3 mm; 0.34″ × 0.30″ × 0.13″) is built on the latest version of Murata's proven 3D MEMS process and uses the company's latest ASIC design and processes. It will be available as single parts on an evaluation PCB, sample bags of four parts, and reels containing either 100 or 1,000 pieces. Article content For more details, please visit the product page, or for inquiries regarding this product, please contact us. Article content About Murata Article content Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. Article content Article content Article content Article content Contacts Article content Article content Article content
National Post
4 hours ago
- National Post
Toshiba Starts Sample Shipments of Second Product in its Smart Motor Control Driver "SmartMCD™" Series
Article content – Relay driver and microcontroller deliver integrated solution for automotive brushed DC motor control – KAWASAKI, Japan — Toshiba Electronic Devices & Storage Corporation ('Toshiba') has started sample shipments of ' TB9M001FTG,' the second product in its Smart Motor Control Driver 'SmartMCD™ [1] ' series. The microcontroller in the SmartMCD™ incorporates a relay driver [2] function and a LIN [3] transceiver function. The new product can drive relays and control two brushed DC motors and is suitable for controlling brushed DC motors in automotive applications. Article content In recent years, as the electrification of automotive equipment has progressed, secondary devices [4] are increasingly required to offer higher performance, enhanced functionality, more compact designs, and fewer components. Toshiba has responded to these requirements, by developing the new product. Article content Article content The new SmartMCD™ has four built-in low-side drivers that can be used for relay drivers and other applications, enabling forward and reverse control [5] of two brushed DC motors. It also features a built-in microcontroller (Arm ® Cortex ® -M0 core), high-capacity flash memory, two high-side drivers for power-supply applications, a LIN transceiver, and a power supply system that can operate at the automotive battery level. All of these functions are integrated into a compact VQFN48 package (7×7 mm typ.). Article content In addition to controlling brushed DC motors in automotive applications, such as power sunroofs, electric wipers, power windows, and power seats, the driver is also capable of controlling various sensors and actuators. Furthermore, through LIN control from the main ECU, it can be utilized as a secondary device for a wide range of applications. This enables efficient control of various automotive functions and supports a broad spectrum of automotive applications. Article content Toshiba will continue to expand its lineup of SmartMCD™ series and will contribute to downsizing of automotive systems and reducing the number of components used. Article content Notes: [1] SmartMCD™: A series of ICs developed by Toshiba Electronic Devices & Storage Corporation that integrate motor control functions and a microcontroller. [2] Relay driver: An electronic circuit designed to safely and reliably operate a relay (electromagnetic switch) that controls large currents using small current and voltage signals from a microcontroller or control circuit. [3] Local interconnect network (LIN): A serial communication protocol used primarily for communication between electronic control units (ECU) in vehicles. [4] Secondary device: A device that is responsible for supporting the main ECU. [5] When using two Single pole double throw (SPDT) relays. Article content Applications Article content Automotive equipment Article content Electric sunroof Electric wiper Power window Power seat and more. Article content Features Article content Main Specifications Article content Note: [7] ASIL-A: ASIL stands for Automotive Safety Integrity Level, which is a functional safety requirement level defined based on the ISO 26262 standard for automotive functional safety. ASIL-A is the lowest safety requirement level within this classification and is applied when a malfunction of the function is assessed to have a relatively low impact on human life or the vehicle. Article content Related Contents Article content Follow the links below for more on the new product. Article content Article content Analog Devices Article content * Arm and Cortex are registered trademarks of Arm Limited (or its subsidiaries) in the US and/or elsewhere. * SmartMCD™ is a trademark of Toshiba Electronic Devices & Storage Corporation. * Other company names, product names, and service names may be trademarks of their respective companies. * Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice. Article content Toshiba Electronic Devices & Storage Corporation, a leading supplier of advanced semiconductor and storage solutions, draws on over half a century of experience and innovation to offer customers and business partners outstanding discrete semiconductors, system LSIs and HDD products. Article content Its 19,400 employees around the world share a determination to maximize product value, and to promote close collaboration with customers in the co-creation of value and new markets. The company looks forward to building and to contributing to a better future for people everywhere. Article content Article content Article content Article content Contacts Article content Customer inquiries: Article content Article content Analog Device Sales & Marketing Dept Article content Article content Tel: +81-44-548-2219 Article content Article content Contact Us Article content
Globe and Mail
5 hours ago
- Globe and Mail
Schizophrenia Clinical Trials Appears Robust With 55+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Schizophrenia Pipeline Insight' report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Schizophrenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Schizophrenia Treatment Landscape. Click here to read more @ Schizophrenia Pipeline Outlook Key Takeaways from the Schizophrenia Pipeline Report In June 2025, Bristol-Myers Squibb announced a study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia. In June 2025, Teva Branded Pharmaceutical Products R&D Inc. conducted a study will be composed of 2 periods: Period 1 (the double-blind, placebo-controlled, efficacy and safety period) and Period 2 (open-label long term safety period). For each participant, the duration of Period 1 will be 8 weeks, and the duration of Period 2 will be up to 48 weeks. In Period 1, participants will be randomized to one of 3 TV-44749 treatment groups or a placebo group in a 1:1:1:1 ratio. DelveInsight's Schizophrenia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Schizophrenia treatment. The leading Schizophrenia Companies such as Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others. Promising Schizophrenia Therapies such as x Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others. Stay informed about the cutting-edge advancements in Schizophrenia treatments. Download for updates and be a part of the revolution in cancer care @ Schizophrenia Clinical Trials Assessment Schizophrenia Emerging Drugs Profile Ulotaront: Sunovion Pharmaceuticals SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia and other psychiatric conditions. Sunovion discovered SEP-363856 in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Currently, the drug is in the Phase III stage of its development for the treatment of Schizophrenia Emraclidine: Abbvie Emraclidine is a selective M4 receptor PAM, meaning it selectively targets the M4 receptor to harness the anti-psychotic effect believed to be associated with this receptor while minimizing the side effects associated with other pan-muscarinic agonists. The company believes emraclidine has the potential to provide a significant medical advancement as the muscarinic acetylcholine pathway has long been associated with mediation of neurotransmitter imbalance and psychosis. Emraclidine is the only selective M4 receptor PAM currently in clinical development. Currently, the drug is in the Phase II stage of its development for the treatment of Schizophrenia. CY 6463: Cyclerion Therapeutics CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. As an sGC stimulator, CY6463 acts as a positive allosteric modulator to sensitize the sGC enzyme to NO, increase the production of cGMP, and thereby amplify endogenous NO signaling. By compensating for deficient NO-sGC-cGMP signaling, CY6463 and other sGC stimulators may have broad therapeutic potential as a treatment to improve cognition and function in people with serious CNS diseases. Currently, the drug is in the Phase I stage of its development for the treatment of Schizophrenia. Learn more about Schizophrenia Drugs opportunities in our groundbreaking Schizophrenia Research and development projects @ Schizophrenia Unmet Needs Schizophrenia Companies Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others. Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Schizophrenia Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Discover the latest advancements in Schizophrenia treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Schizophrenia Market Drivers and Barriers, and Future Perspectives Scope of the Schizophrenia Pipeline Report Coverage- Global Schizophrenia Companies- Sunovion Pharmaceuticals, Denovo BioPharma, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals and others. Schizophrenia Therapies- Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others Schizophrenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Schizophrenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Schizophrenia Pipeline on our website @ Schizophrenia Emerging Drugs and Companies Table of Content Introduction Executive Summary Schizophrenia: Overview Pipeline Therapeutics Therapeutic Assessment Schizophrenia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) LYN-005: Lyndra Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) Emraclidine: Abbvie Drug profiles in the detailed report….. Early Stage Products (Phase I) KYN-5356: Kynexis Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Schizophrenia Key Companies Schizophrenia Key Products Schizophrenia- Unmet Needs Schizophrenia- Market Drivers and Barriers Schizophrenia- Future Perspectives and Conclusion Schizophrenia Analyst Views Schizophrenia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
